Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.06
DHR's Cash-to-Debt is ranked lower than
95% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. DHR: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
DHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.16 Max: 1.33
Current: 0.06
0
1.33
Equity-to-Asset 0.55
DHR's Equity-to-Asset is ranked lower than
61% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DHR: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
DHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.51 Max: 0.67
Current: 0.55
0.16
0.67
Debt-to-Equity 0.43
DHR's Debt-to-Equity is ranked lower than
60% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. DHR: 0.43 )
Ranked among companies with meaningful Debt-to-Equity only.
DHR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.13  Med: 0.36 Max: 3.82
Current: 0.43
0.13
3.82
Debt-to-EBITDA 2.70
DHR's Debt-to-EBITDA is ranked lower than
68% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. DHR: 2.70 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DHR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.79  Med: 1.44 Max: 4.21
Current: 2.7
0.79
4.21
Interest Coverage 18.30
DHR's Interest Coverage is ranked lower than
58% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. DHR: 18.30 )
Ranked among companies with meaningful Interest Coverage only.
DHR' s Interest Coverage Range Over the Past 10 Years
Min: 12.58  Med: 16.69 Max: 22.1
Current: 18.3
12.58
22.1
Piotroski F-Score: 7
Altman Z-Score: 3.16
Beneish M-Score: -2.56
WACC vs ROIC
7.00%
7.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 15.73
DHR's Operating Margin % is ranked higher than
85% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DHR: 15.73 )
Ranked among companies with meaningful Operating Margin % only.
DHR' s Operating Margin % Range Over the Past 10 Years
Min: 13.79  Med: 16.08 Max: 17.33
Current: 15.73
13.79
17.33
Net Margin % 13.36
DHR's Net Margin % is ranked higher than
86% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. DHR: 13.36 )
Ranked among companies with meaningful Net Margin % only.
DHR' s Net Margin % Range Over the Past 10 Years
Min: 10.3  Med: 13.9 Max: 23.26
Current: 13.36
10.3
23.26
ROE % 9.93
DHR's ROE % is ranked higher than
67% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. DHR: 9.93 )
Ranked among companies with meaningful ROE % only.
DHR' s ROE % Range Over the Past 10 Years
Min: 10.74  Med: 13.64 Max: 17.42
Current: 9.93
10.74
17.42
ROA % 5.33
DHR's ROA % is ranked higher than
71% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. DHR: 5.33 )
Ranked among companies with meaningful ROA % only.
DHR' s ROA % Range Over the Past 10 Years
Min: 5.46  Med: 7.75 Max: 9.03
Current: 5.33
5.46
9.03
ROC (Joel Greenblatt) % 72.07
DHR's ROC (Joel Greenblatt) % is ranked higher than
89% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. DHR: 72.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 59.73  Med: 82.44 Max: 118.82
Current: 72.07
59.73
118.82
3-Year Revenue Growth Rate -2.10
DHR's 3-Year Revenue Growth Rate is ranked lower than
68% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. DHR: -2.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 9.7 Max: 47.6
Current: -2.1
-9.7
47.6
3-Year EBITDA Growth Rate -3.30
DHR's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. DHR: -3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19  Med: 11.7 Max: 51.5
Current: -3.3
-19
51.5
3-Year EPS without NRI Growth Rate -5.50
DHR's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. DHR: -5.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: 14.7 Max: 92
Current: -5.5
-33.7
92
» DHR's 30-Y Financials

Financials (Next Earnings Date: 2018-01-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

DHR Guru Trades in Q3 2016

George Soros 7,970 sh (New)
Robert Olstein 47,000 sh (New)
Joel Greenblatt 596,095 sh (New)
Caxton Associates 120,000 sh (New)
Louis Moore Bacon 38,781 sh (+949.27%)
Paul Tudor Jones 65,140 sh (+499.87%)
Ray Dalio 75,600 sh (+245.44%)
Steven Cohen 338,100 sh (+126.36%)
Jim Simons 857,000 sh (+60.49%)
Ruane Cunniff 1,821,908 sh (+17.86%)
Daniel Loeb 4,500,000 sh (+16.88%)
First Eagle Investment 2,450,049 sh (+5.39%)
Ken Fisher 5,760 sh (+1.11%)
Chuck Akre 1,500,000 sh (unchged)
John Hussman 30,000 sh (unchged)
Mairs and Power Sold Out
Manning & Napier Advisors, Inc Sold Out
Pioneer Investments Sold Out
Murray Stahl 36,171 sh (-0.08%)
John Griffin 2,246,000 sh (-3.14%)
Dodge & Cox 5,715,408 sh (-14.11%)
Mario Gabelli 10,751 sh (-50.57%)
Jeremy Grantham 3,826 sh (-60.63%)
John Burbank 40,000 sh (-70.64%)
» More
Q4 2016

DHR Guru Trades in Q4 2016

Paul Tudor Jones 484,432 sh (+643.68%)
Steven Cohen 663,300 sh (+96.18%)
Jim Simons 1,522,100 sh (+77.61%)
First Eagle Investment 3,157,097 sh (+28.86%)
Robert Olstein 55,000 sh (+17.02%)
Chuck Akre 1,655,300 sh (+10.35%)
Mario Gabelli 11,196 sh (+4.14%)
John Hussman 30,000 sh (unchged)
George Soros Sold Out
Caxton Associates Sold Out
Ray Dalio Sold Out
John Burbank Sold Out
Murray Stahl 35,587 sh (-1.61%)
Ruane Cunniff 1,733,275 sh (-4.86%)
Dodge & Cox 5,221,273 sh (-8.65%)
Ken Fisher 5,127 sh (-10.99%)
Jeremy Grantham 3,226 sh (-15.68%)
John Griffin 1,760,000 sh (-21.64%)
Daniel Loeb 3,250,000 sh (-27.78%)
Joel Greenblatt 420,700 sh (-29.42%)
» More
Q1 2017

DHR Guru Trades in Q1 2017

Caxton Associates 7,300 sh (New)
Ray Dalio 16,638 sh (New)
Louis Moore Bacon 125,201 sh (+222.84%)
Robert Olstein 65,000 sh (+18.18%)
Ken Fisher 5,224 sh (+1.89%)
Chuck Akre 1,655,300 sh (unchged)
John Hussman 30,000 sh (unchged)
John Griffin 1,760,000 sh (unchged)
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Dodge & Cox 5,099,223 sh (-2.34%)
Ruane Cunniff 1,664,622 sh (-3.96%)
Murray Stahl 34,135 sh (-4.08%)
Jim Simons 1,459,300 sh (-4.13%)
Mario Gabelli 10,696 sh (-4.47%)
Daniel Loeb 3,100,000 sh (-4.62%)
First Eagle Investment 2,623,552 sh (-16.90%)
Joel Greenblatt 269,309 sh (-35.99%)
» More
Q2 2017

DHR Guru Trades in Q2 2017

Paul Tudor Jones 30,918 sh (New)
Steven Cohen 697,114 sh (New)
Louis Moore Bacon 214,900 sh (+71.64%)
Jim Simons 1,697,400 sh (+16.32%)
First Eagle Investment 2,925,603 sh (+11.51%)
Daniel Loeb 3,300,000 sh (+6.45%)
Ken Fisher 5,423 sh (+3.81%)
Dodge & Cox 5,250,773 sh (+2.97%)
Robert Olstein 65,000 sh (unchged)
Chuck Akre 1,655,300 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Mario Gabelli 10,616 sh (-0.75%)
Ruane Cunniff 1,648,054 sh (-1.00%)
Murray Stahl 33,664 sh (-1.38%)
Caxton Associates 7,100 sh (-2.74%)
John Griffin 1,487,700 sh (-15.47%)
» More
» Details

Insider Trades

Latest Guru Trades with DHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-06-30 Add 2.97%0.01%$81.7 - $86.84 $ 90.797%5,250,773
First Eagle Investment 2017-06-30 Add 11.51%0.06%$81.7 - $86.84 $ 90.797%2,925,603
Ruane Cunniff 2017-06-30 Reduce -1.00%0.01%$81.7 - $86.84 $ 90.797%1,648,054
Mario Gabelli 2017-06-30 Reduce -0.75%$81.7 - $86.84 $ 90.797%10,616
Ken Fisher 2017-06-30 Add 3.81%$81.7 - $86.84 $ 90.798%5,423
Joel Greenblatt 2017-06-30 Sold Out 0.29%$81.7 - $86.84 $ 90.797%0
Dodge & Cox 2017-03-31 Reduce -2.34%0.01%$78.78 - $87.76 $ 90.798%5,099,223
First Eagle Investment 2017-03-31 Reduce -16.90%0.11%$78.78 - $87.76 $ 90.798%2,623,552
Ruane Cunniff 2017-03-31 Reduce -3.96%0.05%$78.78 - $87.76 $ 90.798%1,664,622
Joel Greenblatt 2017-03-31 Reduce -35.99%0.15%$78.78 - $87.76 $ 90.798%269,309
Robert Olstein 2017-03-31 Add 18.18%0.11%$78.78 - $87.76 $ 90.798%65,000
Mario Gabelli 2017-03-31 Reduce -4.47%$78.78 - $87.76 $ 90.798%10,696
Ken Fisher 2017-03-31 Add 1.89%$78.78 - $87.76 $ 90.798%5,224
Dodge & Cox 2016-12-31 Reduce -8.65%0.04%$75.86 - $80.94 $ 90.7916%5,221,273
First Eagle Investment 2016-12-31 Add 28.86%0.14%$75.86 - $80.94 $ 90.7916%3,157,097
Ruane Cunniff 2016-12-31 Reduce -4.86%0.07%$75.86 - $80.94 $ 90.7916%1,733,275
Chuck Akre 2016-12-31 Add 10.35%0.22%$75.86 - $80.94 $ 90.7916%1,655,300
Joel Greenblatt 2016-12-31 Reduce -29.42%0.18%$75.86 - $80.94 $ 90.7916%420,700
Robert Olstein 2016-12-31 Add 17.02%0.08%$75.86 - $80.94 $ 90.7916%55,000
Mario Gabelli 2016-12-31 Add 4.14%$75.86 - $80.94 $ 90.7916%11,196
Ken Fisher 2016-12-31 Reduce -10.99%$75.86 - $80.94 $ 90.7916%5,127
George Soros 2016-12-31 Sold Out 0.02%$75.86 - $80.94 $ 90.7916%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:TMO, NYSE:A, NYSE:Q, NYSE:LH, NAS:IDXX, TSE:6869, NYSE:DGX, XPAR:ERF, SZSE:300676, XPAR:BIM, NYSE:PKI, NAS:QGEN, NYSE:BIO, XTER:SRT3, NAS:ICLR, NAS:DXCM, NAS:EXAS, NAS:INCR, NYSE:CRL, MIL:DIA » details
Traded in other countries:DHER34.Brazil, DAP.Germany, DHR.Mexico, DHR.Switzerland, 0R2B.UK,
Headquarter Location:USA
Danaher Corp designs, manufactures and markets professional, medical, industrial and commercial products and services. It markets its products under the brand of Beckman Coulter, Aperio, Dexis, Chemtreat and others.

After the spin-off of Fortive in 2016, Danaher is a diversified and mostly healthcare-focused instrument and supplies manufacturer. After the spin, Danaher retains four main business segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. Each segment represents approximately 32%, 31%, 16%, and 21% of revenue, respectively.

Guru Investment Theses on Danaher Corp

Daniel Loeb Comments on Danaher - Apr 27, 2016

Danaher (DHR) is a diversified multi-industrial company with an increasing exposure to life science and healthcare-oriented businesses. Operating across five different business segments and built up through over 400 acquisitions over the company’s history, the cornerstone for Danaher’s successful integration and value creation strategy has been the

Danaher Business System (DBS). Adapted from Japanese principles of kaizen, DBS has evolved into a set of processes and corporate culture revolving around continuous improvement, helping to drive organic growth and annual margin improvement across Danaher’s portfolio.

In May 2015, Danaher announced the acquisition of a filtration industry leader, Pall Corp, as well as the subsequent split of Danaher into two companies. The split, to be effectuated Q3 2016, will highlight value at both New Danaher – a collection of Danaher’s life science, medical and lower cyclicality businesses – and the spin-off, Fortive – an industrial focused “mini-Danaher”.

New Danaher, representing the large majority of post-split value, will have 60% consumables sales mix, 4% organic growth, 100bps of annual margin expansion, and>100% FCF conversion, an algorithm that will continue the Danaher tradition of compounded earnings growth. The attractive end-market mix, earnings growth, and deep bench of DBS operators will make New Danaher a premium life sciences company that should trade at the high end of its peer group.

Fortive, akin to what Danaher originally looked like two decades ago, will have greatly increased M&A optionality and the ability to deploy free cash flow into assets which have historically received less focus within the Danaher portfolio. With the same DBS roots and team of disciplined operators, Fortive will also provide a multi-year compounding opportunity.

We initiated a position following the announcements last summer which mark a transformational step in Danaher’s decade-long efforts to continuously improve its portfolio of businesses. Despite Danaher’s portfolio of businesses looking more attractive than ever, its current valuation premium to the S&P 500 is modest and remains well below its ten year historical average premium. Over the last ten years, Danaher has compounded at 2x the rate of the S&P 500. We recently added to the position after a meeting with the company reinforced our confidence not only in their operations but also in the company’s culture and importance of their values and principles in driving future success.

From Daniel Loeb (Trades, Portfolio)'s first quarter 2016 shareholder letter.

Check out Daniel Loeb latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 26.86
DHR's PE Ratio is ranked higher than
68% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. DHR: 26.86 )
Ranked among companies with meaningful PE Ratio only.
DHR' s PE Ratio Range Over the Past 10 Years
Min: 9.61  Med: 14.69 Max: 27.74
Current: 26.86
9.61
27.74
Forward PE Ratio 21.01
DHR's Forward PE Ratio is ranked higher than
70% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. DHR: 21.01 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.02
DHR's PE Ratio without NRI is ranked higher than
69% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. DHR: 27.02 )
Ranked among companies with meaningful PE Ratio without NRI only.
DHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.58  Med: 15.55 Max: 38.03
Current: 27.02
9.58
38.03
Price-to-Owner-Earnings 23.84
DHR's Price-to-Owner-Earnings is ranked higher than
63% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. DHR: 23.84 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.59  Med: 11.63 Max: 26.84
Current: 23.84
7.59
26.84
PB Ratio 2.49
DHR's PB Ratio is ranked higher than
73% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. DHR: 2.49 )
Ranked among companies with meaningful PB Ratio only.
DHR' s PB Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.86 Max: 2.67
Current: 2.49
1.19
2.67
PS Ratio 3.59
DHR's PS Ratio is ranked higher than
53% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. DHR: 3.59 )
Ranked among companies with meaningful PS Ratio only.
DHR' s PS Ratio Range Over the Past 10 Years
Min: 1.01  Med: 1.88 Max: 4.35
Current: 3.59
1.01
4.35
Price-to-Free-Cash-Flow 23.89
DHR's Price-to-Free-Cash-Flow is ranked higher than
50% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. DHR: 23.89 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.59  Med: 12.95 Max: 25.3
Current: 23.89
7.59
25.3
Price-to-Operating-Cash-Flow 19.43
DHR's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. DHR: 19.43 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.81  Med: 11.49 Max: 20.11
Current: 19.43
6.81
20.11
EV-to-EBIT 26.13
DHR's EV-to-EBIT is ranked higher than
50% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. DHR: 26.13 )
Ranked among companies with meaningful EV-to-EBIT only.
DHR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 12.5 Max: 35.6
Current: 26.13
8
35.6
EV-to-EBITDA 18.19
DHR's EV-to-EBITDA is ranked higher than
58% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. DHR: 18.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
DHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.3 Max: 26.1
Current: 18.19
6.7
26.1
EV-to-Revenue 4.12
DHR's EV-to-Revenue is ranked lower than
51% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. DHR: 4.12 )
Ranked among companies with meaningful EV-to-Revenue only.
DHR' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.1 Max: 5.4
Current: 4.12
1.2
5.4
Shiller PE Ratio 27.09
DHR's Shiller PE Ratio is ranked higher than
83% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 49.53 vs. DHR: 27.09 )
Ranked among companies with meaningful Shiller PE Ratio only.
DHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.2  Med: 22.77 Max: 34.19
Current: 27.09
15.2
34.19
Current Ratio 1.43
DHR's Current Ratio is ranked lower than
74% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. DHR: 1.43 )
Ranked among companies with meaningful Current Ratio only.
DHR' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.43 Max: 2.23
Current: 1.43
0.9
2.23
Quick Ratio 1.00
DHR's Quick Ratio is ranked lower than
81% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DHR: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
DHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 0.98 Max: 1.82
Current: 1
0.56
1.82
Days Inventory 81.20
DHR's Days Inventory is ranked lower than
51% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. DHR: 81.20 )
Ranked among companies with meaningful Days Inventory only.
DHR' s Days Inventory Range Over the Past 10 Years
Min: 63.09  Med: 71.38 Max: 108.16
Current: 81.2
63.09
108.16
Days Sales Outstanding 66.63
DHR's Days Sales Outstanding is ranked higher than
51% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. DHR: 66.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
DHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.46  Med: 67.29 Max: 97.75
Current: 66.63
54.46
97.75
Days Payable 68.74
DHR's Days Payable is ranked higher than
55% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. DHR: 68.74 )
Ranked among companies with meaningful Days Payable only.
DHR' s Days Payable Range Over the Past 10 Years
Min: 59.9  Med: 70.23 Max: 110.7
Current: 68.74
59.9
110.7

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.60
DHR's Dividend Yield % is ranked lower than
64% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.89 vs. DHR: 0.60 )
Ranked among companies with meaningful Dividend Yield % only.
DHR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.14  Med: 0.25 Max: 0.84
Current: 0.6
0.14
0.84
Dividend Payout Ratio 0.16
DHR's Dividend Payout Ratio is ranked higher than
76% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DHR: 0.16 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DHR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.03  Med: 0.03 Max: 0.22
Current: 0.16
0.03
0.22
3-Year Dividend Growth Rate 78.60
DHR's 3-Year Dividend Growth Rate is ranked higher than
97% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DHR: 78.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DHR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13.2 Max: 78.6
Current: 78.6
0
78.6
Forward Dividend Yield % 0.62
DHR's Forward Dividend Yield % is ranked lower than
67% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. DHR: 0.62 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.63
DHR's 5-Year Yield-on-Cost % is ranked higher than
89% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. DHR: 5.63 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DHR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.31  Med: 2.35 Max: 7.89
Current: 5.63
1.31
7.89
3-Year Average Share Buyback Ratio 0.30
DHR's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. DHR: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.3  Med: -1.5 Max: 0.3
Current: 0.3
-7.3
0.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.29
DHR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. DHR: 1.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DHR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.18 Max: 4.64
Current: 1.29
0.52
4.64
Price-to-Median-PS-Value 1.91
DHR's Price-to-Median-PS-Value is ranked lower than
85% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. DHR: 1.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DHR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.87 Max: 2.02
Current: 1.91
0.12
2.02
Earnings Yield (Greenblatt) % 3.83
DHR's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. DHR: 3.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 8 Max: 12.6
Current: 3.83
2.8
12.6
Forward Rate of Return (Yacktman) % 2.27
DHR's Forward Rate of Return (Yacktman) % is ranked lower than
67% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. DHR: 2.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.1  Med: 19.4 Max: 27.2
Current: 2.27
2.1
27.2

More Statistics

Revenue (TTM) (Mil) $17,828.30
EPS (TTM) $ 3.38
Beta0.97
Short Percentage of Float0.65%
52-Week Range $76.27 - 91.64
Shares Outstanding (Mil)695.61

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 18,079 18,875 19,554
EPS ($) 3.94 4.31 4.55
EPS without NRI ($) 3.94 4.31 4.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.29%
Dividends per Share ($) 0.56 0.61 0.72

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}